查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1978350

全球Guillain-Barré二氏症候群（GBS）市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Guillain-Barre Syndrome (GBS) Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計Guillain-Barré二氏症候群(GBS) 市場將從 2025 年的 7.9 億美元成長到 2034 年的 14.1 億美元，2026 年至 2034 年的複合年成長率為 6.66%。

隨著人們對罕見神經系統疾病的認知不斷提高以及診斷能力的進步，全球Guillain-Barré二氏症候群（GBS）市場正在成長。Guillain-Barré二氏症候群是嚴重的自體免疫疾病，會影響周邊神經系統，需要及時進行醫療干預。醫療保健支出的增加和神經學研究的進步帶來了更有效的治療方案，從而推動了市場擴張。

格林-巴利症候群（GBS）市場的主要促進因素包括自體免疫疾病和感染疾病的發生率不斷上升，這些疾病和感染都可能導致此症候群。由於醫療基礎設施的改善和早期診斷的普及，疾病管理正在不斷進步。此外，製藥公司和研究機構正在投資臨床試驗，以開發更有效的治療方法和輔助療法，這有望促進整體醫療環境的改善。

未來，隨著免疫療法和個人化醫療的進步，市場預計將持續成長。對罕見疾病研究的日益重視，以及政府對神經系統疾病治療的支持政策，可望改善患者的治療效果。隨著醫療技術的進步和公眾意識的不斷提高，Guillain-Barré二氏症候群市場預計將在全球範圍內穩步發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球Guillain-Barré二氏症候群（GBS）市場：依治療方法

  • 市場分析、洞察與預測
  • 靜脈注射免疫球蛋白（IVIG）
  • 血漿置換療法
  • 其他

第5章：全球Guillain-Barré二氏症候群（GBS）市場：按類型分類

  • 市場分析、洞察與預測
  • 急性發炎性去髓鞘化多發性神經病變（AIDP）
  • 慢性發炎性去髓鞘化多發性神經根神經病變（CIDP）
  • 米勒-費雪症候群（MFS）
  • 急性運動軸索性神經病變（AMAN）
  • 其他

第6章 全球Guillain-Barré二氏症候群（GBS）市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 腸外
  • 口服

第7章 全球Guillain-Barré二氏症候群（GBS）市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 其他藥房

第8章 全球Guillain-Barré二氏症候群（GBS）市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie Inc
    • Biogen Inc
    • Cadila Healthcare Limited
    • CSL Limited
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline Plc
    • Grifols
    • SA
    • LGM Pharma
    • Merck & Co. Inc
    • Octapharma AG
    • Pfizer Inc
    • Takeda Pharmaceutical Company Limited
簡介目錄
Product Code: VMR112114696

The Guillain-Barre Syndrome (GBS) Market size is expected to reach USD 1.41 Billion in 2034 from USD 0.79 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The Global Guillain-Barre Syndrome (GBS) Market is growing as awareness of rare neurological disorders increases and diagnostic capabilities improve. Guillain-Barre syndrome is a serious autoimmune condition that affects the peripheral nervous system and requires timely medical intervention. Rising healthcare spending and advancements in neurology research have contributed to the growing availability of effective treatment options, thereby supporting the market's expansion.

Key drivers of the GBS market include the increasing incidence of autoimmune diseases and infections that may trigger the syndrome. Improved healthcare infrastructure and early diagnosis have enabled better disease management. Additionally, pharmaceutical companies and research institutions are investing in clinical trials to develop more effective therapies and supportive treatments, which is expected to boost the overall treatment landscape.

In the future, the market is anticipated to expand with advancements in immunotherapy and personalized medicine. Increasing focus on rare disease research, along with government initiatives supporting neurological disorder treatment, will likely improve patient outcomes. As medical technologies evolve and awareness continues to grow, the Guillain-Barre syndrome market is expected to see steady progress worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

  • Intravenous Immunoglobulin (IVIG)
  • Plasma Exchange
  • Others

By Type

  • Acute inflammatory demyelinating polyneuropathy (AIDP)
  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
  • Miller fisher syndrome (MFS)
  • Acute motor axonal neuropathy (AMAN)
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Pharmacies

COMPANIES PROFILED

  • AbbVie Inc, Biogen Inc, Cadila Healthcare Limited, CSL Limited, F HoffmannLa Roche Ltd, GlaxoSmithKline plc, Grifols, SA, LGM Pharma, Merck Co Inc, Octapharma AG, Pfizer Inc, Takeda Pharmaceutical Company Limited
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Therapeutics
  • 4.2. Intravenous Immunoglobulin (IVIG) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Plasma Exchange Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Acute inflammatory demyelinating polyneuropathy (AIDP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Miller fisher syndrome (MFS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Acute motor axonal neuropathy (AMAN) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Other Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Therapeutics
    • 8.2.2 By Type
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Therapeutics
    • 8.3.2 By Type
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Therapeutics
    • 8.4.2 By Type
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Therapeutics
    • 8.5.2 By Type
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Therapeutics
    • 8.6.2 By Type
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AbbVie Inc
    • 10.2.2 Biogen Inc
    • 10.2.3 Cadila Healthcare Limited
    • 10.2.4 CSL Limited
    • 10.2.5 F. Hoffmann-La Roche Ltd
    • 10.2.6 GlaxoSmithKline Plc
    • 10.2.7 Grifols
    • 10.2.8 S.A
    • 10.2.9 LGM Pharma
    • 10.2.10 Merck & Co. Inc
    • 10.2.11 Octapharma AG
    • 10.2.12 Pfizer Inc
    • 10.2.13 Takeda Pharmaceutical Company Limited